Skip to content
Who We Are
Executive Team
Board of Directors
Scientific Advisors
THR-149
News
Investors
Let’s Talk
Menu
Who We Are
Executive Team
Board of Directors
Scientific Advisors
THR-149
News
Investors
Let’s Talk
Targeting plasma kallikrein with a novel bicyclic peptide inhibitor (THR-149) reduces retinal inflammation and reactive gliosis in a diabetic rat model
Van Bergen, Tine – Euretina – 9-12 September 2021
Publication date:
September, 2021
Attachment:
Targeting Pkal with a novel bicyclic peptide inhibitor (THR-149) reduces retinal inflammation and reactive gliosis_EURETINA 2021.pdf